Innovative COPD Drug Provides Quality Treatment at High Cost
There are times when working in managed care leads me to an internal conflict while reviewing a drug. One of the conflicts that happens often is seeing a new drug come to market that offers an interesting bit of technology or great research but the financial proposition of the product does not lead to as much excitement. I recently had such an experience as I learned about the newly approved chronic obstructive pulmonary disease (COPD) treatment Lonhala Magnair (glycopyrrolate inhalation solution; Sunovian Pharmaceuticals).
Lonhala Magnair is a nebulized long-acting muscarinic antagonist (LAMA) product that uses glycopyrrolate as its active ingredient. I had a chance to see a demonstration version of the nebulizer device and this is when the clinical and scientific part of me really got excited. It comes in a fairly compact form that will be easy for patients to take with them on the go. It was pretty easy to learn how to put together and use and looked to put out a consistent cloud of medication over the few minutes it takes to deliver a dose. Being a LAMA, patients will only need to dose the medication twice per day, which is a pretty convenient dose schedule. It really feels like the scientists and engineers who have worked on developing this system really put a lot of effort into making it as patient friendly as possible.
However, as I moved past the piece of me excited about the design of this product, the realization of the potential impact of the cost set in. Seeing a monthly average wholesale price (AWP) over $1300 came at a bit of a shock within this disease state. While most of the agents for treating COPD used today are branded medications, their costs are quite a bit lower than that of Lonhala. In my mind the cost of Lonhala does not disqualify it for use in the COPD population, but I think it will lend to more scrutiny in its coverage and use.
The other medications in the LAMA class available in the United States come in inhaler type devices. While these medications work well for many patients, there are still a number who will fail with inhalers. In order to help them get the maximum benefit from using a muscarinic antagonist, their treatment is usually moved to a nebulized muscarinic medication. Using a nebulized form can increase the length and depth of exposure to the medication when compared to an inhaler device which leads to better outcomes for many. This means that Lonhala does have potential to provide benefit to patients who have previously failed a lower cost inhaler device. I think this will drive most payers to have either some sort of prior authorization or step therapy criteria to ensure their member has tried a lower cost inhaler before moving to Lonhala.
Situations where there may be a perceived imbalance between the science of a drug, its clinical benefit, and its cost are likely to be seen again and again within managed care. Each will have to be taken and considered on a case-by-case basis, but I am also excited to see how our industry works to solve these potential problems as a collective. Finding the balance between clinical value and cost will likely take cooperation between all interested parties in order to continue to provide members with the medications they need at costs that will keep the health care system financially viable.
—Russ J Spjut, PharmD
Russ J Spjut, PharmD, is owner of Formulary Intel Consulting. He is a residency trained pharmacist in managed care with experience in both commercial and Medicare Part D PBM operations. He has been involved in formulary management, P&T committee presentations, clinical program development, formulary strategy, clinical analysis, client management, and review of coverage determination requests for a major health care management company.
For articles by First Report Managed Care, click here
To view the First Report Managed Care print issue, click here


